EU

The cannabis market: helping investors navigate the UK regulatory regime

Matthew Townsend

Last year the global legal cannabis market was estimated to be worth USD12 billion but it is tipped to rise to over USD166 billion by 2025. Liberalisation of the legal framework for cannabis is a significant driver for this growth. Since 1 November 2018, the UK has joined the ranks of over 30 countries legalising Read More

Italy launches urgent tender for the supply of 400 kg of medical cannabis: New opportunities for cannabis producers

Roberta Errico

For the second time, the Italian Ministry of Defence has launched an open tender for an urgent need of cannabis for therapeutic purposes by the Florence Pharmaceutical Chemical Plant. The estimated reference price of the tender is EUR 1,520,000 (net of VAT) for 400 kg, which represents an average of EUR 3.8 per gram. This Read More

EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation

Sophie ten Bosch

At the latest meeting of EU agriculture ministers, and following a report by the Danish Council of Ethics, 14 EU member states, led by the Netherlands and Estonia, called for the European Commission to re-evaluate the EU’s stance on genetically modified organisms (GMOs), in particular those created by new plant breeding techniques. In a ruling Read More

CJEU upholds withdrawal of orphan designation based on increased availability

Jacqueline Bore

The EU’s General Court, whose jurisdiction includes the judicial review of decisions made by the EU institutions such as European Medicines Agency, has recently considered an interesting application in relation to a medicinal product that had been granted orphan designation on the little used basis that its significant benefit lay in its potential authorisation in Read More

Dutch competition authority extends excessive pricing inquiry to consider possible supply restrictions on orphan ingredients

Francesca Miotto

Last week, the Dutch Authority for Consumers and Markets (ACM) announced that it is investigating whether the Italian pharmaceutical company Leadiant Biosciences restricted the supply of an important raw material for a patented orphan drug, by entering into exclusive agreements with an unnamed supplier. Such supply restrictions for raw materials could, according to the ACM, Read More